The specialist management of non-temporomandibular orofacial pain: maxillofacial surgery’s known unknown?

Awal, D.; Amin, Kejal; Nova, Carolina Venda; Naqvi, Ambareen; Zakrzewska, Joanna M.

doi:10.1016/j.bjoms.2019.06.024

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The diagnosis and treatment of BMS continue to be a challenge for healthcare providers, principally for dentists and oral and maxillofacial surgeons, who are frequently consulted by these patients for a first‐line therapy (Awal, Amin, Venda‐Nova, Naqvi, & Zakrzewska, 2019). In line with the literature (Adamo et al, 2015; Awal et al., 2019), the patients with BMS included in the study showed an undetected and untreated long‐standing disease, highlighting the fact that a delay in the diagnosis continues to be common in relation to this disease.…”

Section: Discussionmentioning

confidence: 99%

Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open‐label randomized trial

et al. 2020

View full text Add to dashboard Cite

Objectives This randomized open‐label trial compared the efficacy and tolerability of vortioxetine (15 mg/daily) with different antidepressants in the treatment of patients with burning mouth syndrome (BMS). Methods One and hundred fifty BMS patients were randomized into five groups and treated with either vortioxetine, paroxetine (20 mg/daily), sertraline (50 mg/daily), escitalopram (10 mg/daily) or duloxetine (60 mg/daily). The Visual Analogue Scale (VAS), Total Pain Rating Index (T‐PRI), Hamilton Rating Scales for Depression (HAM‐D) and Anxiety (HAM‐A), and Clinical Global Impression Improvement (CGI‐I) and Efficacy scales (CGI‐E) were performed at baseline and after 2, 4, 6, and 12 months of treatment. Any adverse events (AEs) were tabulated for each group. Descriptive statistics, including the Kruskal–Wallis non‐parametric test and the Friedman non‐parametric test for median comparisons between different times, were used. Results All the antidepressants (AD) were associated with a significant decrease in the VAS, T‐PRI, HAM‐A, HAM‐D, CGI‐I, and CGI‐E scores in the long‐term (p < .001). However, the response rate of the vortioxetine group showed a significant reduction after six months. The medians, after 6 months, were as follows: VAS 0.0; T‐PRI 2.0; HAM‐A 7.0; HAM‐D 7.0; CGI‐I 1.0; and CGI‐E 1.0 with a lower incidence of AEs (p < .019). Conclusion Vortioxetine was efficacious with a shorter latency of action and fewer AEs compared with other ADs.

show abstract

Section: Discussionmentioning

confidence: 99%